Axitinib-Avelumab Combination Prompted Responses in Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
While the five-year survival rate for adenoid cystic carcinoma (ACC) is relatively high, this cancer has a high risk of recurrence. Therapeutic options are needed to manage this cancer and…